ProKidney PROK 深 滬
等待開盤 10-29 09:30:00 美东时间
1.52
+0.005
+0.33%
華盛通- 最 高1.595
- 今 開1.47
- 成交量 149.78万股
- 最 低 1.46
- 昨 收 1.515
- 總市值 4.60亿
- 52周最高 2.95
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 1.30
- 委 比 29.14%
- 總股本 3.02亿
- 歷史最高 14.19
- 量 比 1.95
- 振 幅 8.91%
- 歷史最低 0.4603
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅163.5%！BTIG上调Cullinan Therapeutics目标价至41美元，维持"买入"评级
今日重点评级关注：BTIG：维持Cullinan Therapeutics"买入"评级，目标价从40美元升至41美元；Rosenblatt：维持SK海力士"买入"评级，目标价从320美元升至400美元
今天 12:30
Citigroup Maintains Buy on ProKidney, Lowers Price Target to $8
Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.
今天 04:47
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
ProKidney Corp. will present eight abstracts, including one oral presentation, at the American Society of Nephrology’s Kidney Week 2026 in Denver. The abstracts highlight rilparencel's multifactorial mechanism of action, safety profile, and kidney function stabilization in advanced CKD and type 2 diabetes. The oral presentation focuses on graft-adjacent remodeling and vascular integrity in a CKD model. Other posters cover metabolic transitioning,...
10-22 12:00
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
ProKidney Corp. will present eight abstracts, including one oral presentation, at the American Society of Nephrology’s Kidney Week 2026. The abstracts highlight rilparencel’s multifactorial mechanism of action in chronic kidney disease (CKD), with seven non-clinical studies showing evidence of oxidative damage attenuation, metabolic dysregulation, and pro-inflammatory signaling reduction. A clinical abstract presents Phase 2 data indicating safet...
10-02 13:00
ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 15.38 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $150.000 thousand w...
08-11 04:25
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Monday. Shares of Biohaven Ltd (NASDAQ:BHVN) fell sharply in pre-market trading. Biohaven announced enrollment of first patient in its pivotal Phase 3 trial of BHV-1300 for Graves’ disease. B of A Securi...
06-29 20:11
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates ProKidney (NASDAQ:PROK) with a Buy and maintains $12 price target.
05-18 22:59
ProKidney Q1 EPS $(0.14), Inline, Sales $226.000K Beat $143.667K Estimate
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 7.69 percent decrease over losses of $(0.13) per share from the same period last year. The
05-15 23:46
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
ProKidney Corp. has appointed Greg Madison as Chief Commercial Officer to lead the commercialization of rilparencel, a cell therapy for chronic kidney disease (CKD) and diabetes. Madison brings over two decades of experience in biopharma, including successful drug launches and business development. He joins ProKidney during a critical phase as the company advances rilparencel toward potential commercialization. Rilparencel aims to address unmet n...
03-25 20:01
